Human in Motion Robotics, a leading innovator in robotic mobility and humanoid technology, today announced that its innovative self-balancing exoskeleton system, XoMotion, has been selected as an Honouree in the prestigious CES 2025 Innovation Awards programme.
The CES Innovation Awards recognises outstanding design and engineering in consumer technology products across a wide range of categories. XoMotion, a cutting-edge robotic exoskeleton, has been acknowledged for its potential to revolutionise the field of rehabilitation medicine.
“We are honoured to be recognised by the CES Innovation Awards programme,” said Siamak Arzanpour, CEO of Human in Motion Robotics. “This recognition validates our commitment to developing innovative solutions that empower individuals with mobility impairments and support healthcare professionals in delivering exceptional patient care.”
A leap forward in rehabilitation technology
XoMotion stands out due to its ability to mimic natural, human-like movements, making it intuitive and easy to use for both patients and therapists. This innovative exoskeleton, rooted in advanced humanoid robotics, reduces the physical burden on therapists by lifting, assisting, mobilising and training patients, thus enhancing the safety and efficiency of rehabilitation programmes.
Key Features of XoMotion:
- Self-balancing: Ensures stability and safety during use due to its 12 high performance actuators which mimic natural bipedal function.
- Hands-free: Allows for natural movement and normal upper body function.
- Omnidirectional: Capable of performing a wide range of complex ambulatory tasks, providing true functionality.
- Versatile: Suitable for a wide range of conditions, including SCI, stroke and other neurological impairments, and safe for patients from acute to chronic stages of injury.
- Safe: Reduces physical burden on therapists, enabling them to focus on patient care.
Global Expansion
Human in Motion Robotics recently received its Medical Devices Establishment License to market and sell XoMotion in Canada, marking a significant milestone as the first step toward providing widespread global access to patients and care providers. With this approval, XoMotion became the first self-balancing exoskeleton system available for acquisition in Canada. Looking ahead, the company will focus on gaining clearance in other important global markets, including the US, Asia and the EU.
